Androgenic anabolic steroid abuse and the cardiovascular system

Handbook of Experimental Pharmacology

Volumn 195, Issue , 2010, Pages 411-457

  Vanberg, Paul ^a   Atar, Dan ^b  

^a AKER UNIVERSITY HOSPITAL   (Norway)

^b NONE

Author keywords

Anabolic androgenic steroids; Arrhythmia; Blood platelet function; Cardiovascular side effects; Coronary calcification; Hypertension; Left ventricle hypertrophy; Lipid alterations; Myocardial infarction; Relaxation abnormalities; Vascular reactivity

Indexed keywords

ANABOLIC AGENT; ANDROGEN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LIPID; STEROID;

ACUTE HEART INFARCTION; ARTERY THROMBOSIS; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; CORONARY RISK; DRUG ABUSE; ECHOCARDIOGRAPHY; HEART ARRHYTHMIA; HEART DEATH; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE HYPERTROPHY; HUMAN; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; LUNG EMBOLISM; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SUDDEN DEATH; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; BLOOD; BLOOD VESSEL; CALCINOSIS; CARDIOVASCULAR FUNCTION; CHEMICALLY INDUCED DISORDER; DOPING; DRUG EFFECT; ECHOGRAPHY; HEMOSTASIS; THROMBOCYTE;

ANABOLIC AGENTS; ARRHYTHMIAS, CARDIAC; BLOOD PLATELETS; BLOOD VESSELS; CALCINOSIS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; DEATH, SUDDEN; DOPING IN SPORTS; ECHOCARDIOGRAPHY; HEMOSTASIS; HUMANS; LIPIDS; STEROIDS;

EID: 77449137555     PISSN: 01712004     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-79088-4_18     Document Type: Review

References (230)

1. Ajayi AA, Mathur R, Halushka PV. Testosterone increases human platelet thromboxane A2 receptor density and aggregation responses. Circulation. 1995;91:2742-2747.
2. Alén M, Rahkila P, Marniemi J. Serum lipids in power athletes self-administering testosterone and anabolic steroids. Int J Sports Med. 1985;6:139-144.
3. Alvarado RG, Liu JY, Zwolak RM. Danazol and limb-threatening arterial thrombosis: Two case reports. J Vasc Surg. 2001;34:1123-6.
4. Ammar EM, Said SA, Hassan MS. Enhanced vasoconstriction and reduced vasorelaxation induced by testosterone and nandrolone in hypercholesterolemic rabbits. Pharmacol Res. 2004;50:253-255.
5. Anderson RA, Ludlam CA, Wu FC. Haemostatic effects of supraphysiological levels of testosterone in normal men. Thromb Haemost. 1995;74:693-697.
6. Ansell JE, Tiarks C, Fairchild VK. Coagulation abnormalities associated with the use of anabolic steroids. Am Heart J. 1993;125:367-371.
7. Appell H-J, Heller-Umpfenbach B, Feraudi M, et al. Ultrastructural and morphometric investigations on the effects of training and administration of anabolic steroids on the myocardium of guinea pigs. Int J Sports Med. 1983;4:268-274.
8. Applebaum-Bowden D, Haffner SM, Hazzard WR. The dyslipoproteinemia of anabolic steroid therapy: increase in hepatic triglyceride lipase precedes the decrease in high density lipoprotein2 cholesterol. Metabolism. 1987;36:949-952.
9. Appleby M, Fisher M, Martin M. Myocardial infarction, hyperkalaemia and ventricular tachycardia in a young male body-builder. Int J Cardiol. 1994;44:171-174.
10. Baker PJ, Ramey ER, Ramwell PW. Androgen-mediated sex differences of cardiovascular responses in rats. Am J Physiol. 1978;235(2):H242-H246.
11. Barbosa J, Seal US, Doe RP. Effects of anabolic steroids on haptoglobin, orosomucoid, plasminogen, fibrinogen, transferrin, ceruloplasmin, alpha-1-antitrypsin, beta-glucuronidase and total serum proteins. J Clin Endocrinol Metab. 1971;33:388-398.
12. Behrendt H, Boffin H. Myocardial cell lesions caused by an anabolic hormone. Cell Tiss Res. 1977;181:423-426.
13. Beutel A, Bergamaschi CT, Campos RR. Effects of chronic anabolic steroid treatment on tonic and reflex cardiovascular control in male rats. J Steroid Biochem Mol Biol. 2005;93:43-48.
14. Bhargava KP, Dhawan KN, Saxena RC. Enhancement of noradrenaline pressor responses in testosterone-treated cats. Br J Pharmacol Chemother. 1967;31:26-31.
15. Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001;281:E1172-E1181.
16. Blamey SL, McArdle BM, Burns P, et al. A double-blind trial of intramuscular stanozolol in the prevention of postoperative deep vein thrombosis following elective abdominal surgery. Thromb Haemost. 1984;51:71-74.
17. Boggia J, Li Y, Thijs L, et al. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet. 2007;370(9594):1219-1229.
18. Bonetti A, Tirelli F, Catapano A, et al. Side effects of anabolic androgenic steroid abuse. Int J Sports Med. 2008;29(8):679-687.
19. Broekmans AW, Conard J, van Weyenberg RG, et al. Treatment of hereditary protein C deficiency with stanozolol. Thromb Haemost. 1987;57:20-24.
20. Brown BG, Morse J, Zhao XQ et al (2001) Electron-beam tomography coronary calcium scores are superior to Framingham risk variables for predicting the measured proximal stenosis burden. Am J Cardiol 88(2A):23E-26E
21. Brownie AC, Gallant S, Nickerson PA, et al. The occurrence of 11-deoxycorticosterone (DOC)-induced hypertension in the Long-Evans rat. Endocr Res Commun. 1978;5:71-80.
22. Budaj A, Yusuf S, Metha SR, et al. Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation. 2002;106:1622-1626.
23. Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med. 1985;313:1369-1375.
24. Campbell SE, Farb A, Weber KT. Pathologic remodeling of the myocardium in a weightlifter taking anabolic steroids. Blood Press. 1993;2:213-216.
25. Capezzuto A, Achilli A, Serra N. Myocardial infarction in a 21-year-old body builder. Am J Cardiol. 1989;63:1539.
26. Carroll JE, Goodfriend TL. Androgen modulation of adrenal angiotensin receptors. Science. 1984;224:1009-1011.
27. Castelli WP, Anderson K (1986) A population at risk. Prevalence of high cholesterol levels in hypertensive patients in the Framingham Study. Am J Med 80(2A):23-32
28. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992;340:1111-1115.
29. Cheung MC, Albers JJ, Wahl PW, et al. High density lipoproteins during hypolipidemic therapy. A comparative study of four drugs. Atherosclerosis. 1980;35:215-228.
30. Chu K, Kang DW, Kim DE, et al. Cerebral venous thrombosis associated with tentorial subdural hematoma during oxymetholone therapy. J Neurol Sci. 2001;185:27-30.
31. Chung T, Kellehert S, Liu PY, et al. Effects of testosterone and nandrolone on cardiac function: a randomized, placebo-controlled study. Clin Endocrinol. 2007;66:235-245.
32. Clark BM, Schofield RS. Dilated cardiomyopathy and acute liver injury associated with combined use of ephedra, gamma-hydroxybutyrate, and anabolic steroids. Pharmacotherapy. 2005;25:756-761.
33. Cohen LI, Hartford CG, Rogers GG. Lipoprotein (a) and cholesterol in body builders using anabolic androgenic steroids. Med Sci Sports Exerc. 1996;28:176-179.
34. Colan SD, Sanders SP, MacPherson D, et al. Left ventricular diastolic function in elite athletes with physiologic cardiac hypertrophy. J Am Coll Cardiol. 1985;6:545-549.
35. Collins R, Baigent C, Sandercock P, et al. Antiplatelet therapy for thromboprophylaxis: the need for careful consideration of the evidence from randomised trials. Antiplatelet trialists0 collaboration. Br Med J. 1994;309:1215-1217.
36. Crook D, Sidhu M, Seed M, et al. Lipoprotein Lp(a) levels are reduced by danazol, an anabolic steroid. Atherosclerosis. 1992;92:41-47.
37. Cunha TS, Moura MJ, Bernardes CF, et al. Vascular sensitivity to phenylephrine in rats submitted to anaerobic training and nandrolone treatment. Hypertension. 2005;46:1010-1015.
38. D'Andrea A, Limongelli G, Caso P, et al. Association between left ventricular structure and cardiac performance during effort in two morphological forms of athlete's heart. Int J Cardiol. 2002;86(2-3):177-184.
39. D'Andrea A, Caso P, Salerno G, et al. Left ventricular early myocardial dysfunction after chronic misuse of anabolic androgenic steroids: a Doppler myocardial and strain imaging analysis. Br J Sports Med. 2007;41:149-155.
40. De Piccoli B, Giada F, Benettin A, et al. Anabolic steroid use in body builders: an echocardiographic study of left ventricle morphology and function. Int J Sports Med. 1991;12:408-412.
41. Di Bello V, Davide G, Massimiliano B, et al. Effects of anabolic-androgenic steroids on weight-lifters' myocardium: an ultrasonic videodensitometric study. Med Sci Sports Exerc. 1999;31:514-521.
42. Di Paolo M, Agozzino M, Toni C, et al. Sudden anabolic steroid abuse-related death in athletes. Int J Cardiol. 2007;114:114-117.
43. Dickerman RD, Schaller F, Prather I, et al. Sudden cardiac death in a 20-year-old bodybuilder using anabolic steroids. Cardiology. 1995;86:172-173.
44. Dickerman RD, McConathy WJ, Schaller F, et al. Echocardiography in fraternal twin bodybuilders with one abusing anabolic steroids. Cardiology. 1997a;88:50-51.
45. Dickerman RD, McConathy WJ, Zachariah NY. Testosterone, sex hormone-binding globulin, lipoproteins, and vascular disease risk. J Cardiovasc Risk. 1997b;4:363-366.
46. Dickerman RD, Schaller F, Zachariah NY, et al. Left ventricular size and function in elite bodybuilders using anabolic steroids. Clin J Sports Med. 1997c;7:90-93.
47. Dickerman RD, Schaller F, McConathy WJ. Left ventricular wall thickening does occur in elite power athletes with or without anabolic steroid use. Cardiology. 1998;90:145-148.
48. Diener HC, Sacco RL, Yusuf S et al (2008) Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol 7 (10):875-884
49. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/ Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-1622.
50. Duchaine D. Underground steroid handbook II. Venice, CA: HLR Tech Books; 1989.
51. Ebenbichler CF, Kaser S, Bodner J, et al. Hyperhomocysteinemia in bodybuilders taking anabolic steroids. Eur J Int Med. 2001a;12:43-47.
52. Ebenbichler CF, Sturm W, Gänzer H, et al. Flow-mediated, endothelium-dependent vasodilatation is impaired in male body builders taking anabolic-androgenic steroids. Atherosclerosis. 2001b;158:483-490.
53. Ehnholm C, Huttunen JK, Kinnunen PJ, et al. Effect of oxandrolone treatment on the activity of lipoprotein lipase, hepatic lipase and phospholipase A1 of human postheparin plasma. N Engl J Med. 1975;292:1314-1317.
54. Emms H, Lewis GP. Sex and hormonal influences on platelet sensitivity and coagulation in the rat. Br J Pharmacol. 1985;86:557-563.
55. Falkenberg M, Karlsson J, Örtenwall P. Peripheral arterial thrombosis in two young men using anabolic steroids. Eur J Vasc Endovasc Surg. 1997;13:223-226.
56. Ferenchick GS. Anabolic/androgenic steroid abuse and thrombosis: is there a connection? Med Hypotheses. 1991;35:27-31.
57. Ferenchick GS, Adelman S. Myocardial infarction associated with anabolic steroid use in a previously healthy 37-year-old weight lifter. Am Heart J. 1992;124:507-508.
58. Ferenchick G, Schwartz D, Ball M, et al. Androgenic-anabolic steroid abuse and platelet aggregation: a pilot study in weight lifters. Am J Med Sci. 1992;303:78-82.
59. Ferenchick GS, Hirokawa S, Mammen EF, et al. Anabolic-androgenic steroid abuse in weight lifters: evidence for activation of the hemostatic system. Am J Hematol. 1995;49:282-288.
60. Ferrera PC, Putnam DL, Verdile VP. Anabolic steroid use as the possible precipitant of dilated cardiomyopathy. Cardiology. 1997;88:218-220.
61. Fineschi V, Baroldi G, Monciotti F, et al. Anabolic steroid abuse and cardiac sudden death. A pathologic study. Arch Pathol Lab Med. 2001;125:253-255.
62. Fineschi V, Riezzo I, Centini F, et al. Sudden cardiac death during anabolic steroid abuse: morphologic and toxicologic findings in two fatal cases of bodybuilders. Int J Legal Med. 2007;121:48-53.
63. Fisher M, Appleby M, Rittoo D, et al. Myocardial infarction with extensive intracoronary thrombus induced by anabolic steroids. Br J Clin Pract. 1996;50(4):222-223.
64. Frankle MA, Eichberg R, Zachariah SB. Anabolic androgenic steroids and a stroke in an athlete: case report. Arch Phys Med Rehabil. 1988;69:632-633.
65. Freed DL, Banks AJ, Longson D, et al. Anabolic steroids in athletics: crossover double-blind trial on weightlifters. Br Med J. 1975;2:471-473.
66. Friedl KE, Hannan CJ Jr, Jones RE, et al. High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Metabolism. 1990;39:69-74.
67. Frölich J, Kullmer T, Urhausen A, et al. Lipid profile of body builders with and without self-administration of anabolic steroids. Eur J Appl Physiol. 1989;59:98-103.
68. Furlanello F, Bentivegna S, Cappato R, et al. Arrhythmogenic effects of illicit drugs in athletes. Ital Heart J. 2003;4:829-837.
69. Fuster V, Steele PM, Chesebro JH (1985) Role of platelets and thrombosis in coronary atherosclerotic disease and sudden death. J Am Coll Cardiol 5(6 Suppl):175B-184B
70. Fuster V, Moreno PR, Fayad ZA, et al. Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol. 2005;46:937-954.
71. Gaede JT, Montine TJ. Massive pulmonary embolus and anabolic steroid abuse. JAMA. 1992;267:2328-2329.
72. Gagnon DR, Zhang TJ, Brand FN, et al. Hematocrit and the risk of cardiovascular disease - the Framingham study: a 34-year follow-up. Am Heart J. 1994;127:674-682.
73. Gallant S, Alfano J, Chargpin M, et al. The inhibition of rat adrenal cytochrome P-45011 beta gene expression by androgens. Endocr Res. 1992;18:145-161.
74. Glazer G. Atherogenic effects of anabolic steroids on serum lipid levels. A literature review. Arch Int Med. 1991;151:1925-1933.
75. Glazer G, Suchman AL. Lack of demonstrated effect of nandrolone in serum lipids. Metabolism. 1994;43:204-210.
76. Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62:707-714.
77. Gosling RG, Budge MM. Terminology for describing the elastic behavior of arteries. Hypertension. 2003;41:1180-1182.
78. Grace F, Sculthorpe N, Baker J, et al. Blood pressure and rate pressure product response in males using high-dose anabolic androgenic steroids (AAS). J Sci Med Sport. 2003;6:307-312.
79. Graham MR, Grace FM, Boobier W, et al. Homocysteine induced cardiovascular events: a consequence of long term anabolic-androgenic steroid (AAS) abuse. Br J Sports Med. 2006;40:644-648.
80. Greenberg S, George WR, Kadowitz PJ, et al. Androgen-induced enhancement of vascular reactivity. Can J Physiol Pharmacol. 1974;52:14-22.
81. Grollman A, Harrison TR, Williams JR Jr. The effect of various sterol derivatives on the blood pressure of the rat. J Pharmacol Exp Ther. 1940;69:149-155.
82. Güneş Y, Erbaş C, Okuyan E, et al. Myocardial infarction with intracoronary thrombus induced by anabolic steroids. Anatolian J Cardiol. 2004;4:357-358.
83. Haffner SM, Kushwaha RS, Foster DM, et al. Studies on the metabolic mechanism of reduced high density lipoproteins during anabolic steroid therapy. Metabolism. 1983;32:413-420.
84. Halvorsen S, Thorsby PM, Haug E (2004) Acute myocardial infarction in a young man who had been using androgenic anabolic steroids. Tidsskr Nor Lægeforen 124:170-172. Norwegian
85. Hartgens F, Kuipers H, Wijnen JAG, et al. Body composition, cardiovascular risk factors and liver function in long term androgenic-anabolic steroids using bodybuilders three months after drug withdrawal. Int J Sports Med. 1996;17:429-433.
86. Hartgens F, Cheriex EC, Kuipers H. Prospective echocardiographic assessment of androgenic-anabolic steroids effects on cardiac structure and function in strength athletes. Int J Sports Med. 2003;24:344-351.
87. Hartgens F, Rietjens G, Keizer HA, et al. Effects of androgenic-anabolic steroids on apolipopro-teins and lipoprotein (a). Br J Sports Med. 2004;38:253-259.
88. Hausmann R, Hammer S, Betz P. Performance enhancing drugs (doping agents) and sudden death-a case report and review of the literature. Int J Legal Med. 1998;111:261-264.
89. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
90. Herman SM, Robinson JT, McCredie RJ, et al. Androgen deprivation is associated with enhanced endothelium-dependent dilatation in adult men. Arterioscler Thromb Vasc Biol. 1997;17:2004-2009.
91. Higham PD, Campbell RW. QT dispersion. Br Heart J. 1994;71:508-510.
92. Hoff JA, Chomka EV, Krainik AJ, et al. Age and gender distributions of coronary artery calcium detected by electron beam tomography in 35, 246 adults. Am J Cardiol. 2001;87:1335-1339.
93. Holma P. Effect of an anabolic steroid (metandienone) on central and peripheral blood flow in well-trained male athletes. Ann Clin Res. 1977;9:215-221.
94. Hourigan LA, Rainbird AJ, Dooris M (1998) Intracoronary stenting for acute myocardial infarction (AMI) in a 24-year-old man using anabolic androgenic steroids. Aust N Z Med 28:838-839
95. Huie MJ. An acute myocardial infarction occurring in an anabolic steroid user. Med Sci Sports Exerc. 1994;26:408-413.
96. Hurley BF, Seals DR, Hagberg JM, et al. High-density-lipoprotein cholesterol in bodybuilders v powerlifters. Negative effects of androgen use. JAMA. 1984;252:507-513.
97. Jacobs DR Jr, Mebane IL, Bangdiwala SI, et al. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. Am J Epidemiol. 1990;131:32-47.
98. Jaillard AS, Hommel M, Mallaret M. Venous sinus thrombosis associated with androgens in a healthy young man. Stroke. 1994;25(1):212-213.
99. Johnson M, Ramey E, Ramwell PW. Sex and age differences in human platelet aggregation. Nature. 1975;253:355-357.
100. Johnson M, Ramey E, Ramwell PW. Androgen-mediated sensitivity in platelet aggregation. Am J Physiol. 1977;232:H381-H385.
101. Kahn NN, Sinha AK, Spungen AM, et al. Effects of oxandrolone, an anabolic steroid, on hemostasis. Am J Hematol. 2006;81:95-100.
102. Kantor MA, Bianchini A, Bernier D, et al. Androgens reduce HDL2-cholesterol and increase hepatic triglyceride lipase activity. Med Sci Sports Exerc. 1985;17:462-465.
103. Karila TAM, Karjalainen JE, Mäntysaari MJ, et al. Anabolic androgenic steroids produce dose-dependent increase in left ventricular mass in power athletes, and this effect is potentiated by concomitant use of growth hormone. Int J Sports Med. 2003;24:337-343.
104. Kasikcioglu E, Kayserilioglu A, Oflaz H, et al. Aortic distensibility and left ventricular diastolic functions in endurance athletes. Int J Sports Med. 2005;26:165-170.
105. Kasikcioglu E, Oflaz H, Arslan A, et al. Aortic elastic properties in athletes using anabolic-androgenic steroids. Int J Cardiol. 2007;114:132-134.
106. Kasikcioglu E, Oflaz H, Umman B et al (2008) Androgenic anabolic steroids also impair right ventriculer function. Int J Cardiol 134(1):123-125
107. Katz FH, Roper EF. Testosterone effect on renin system in rats. Proc Soc Exp Biol Med. 1977;155:330-333.
108. Kennedy C. Myocardial infarction in association with misuse of anabolic steroids. Ulster Med J. 1993;63:174-176.
109. Kennedy MC, Lawrence C. Anabolic steroid abuse and cardiac death. Med J Aust. 1993;158:346-348.
110. Kinson GA, Layberry RA, Hébert B. Influences of anabolic androgens on cardiac growth and metabolism in the rat. Can J Physiol Pharmcol. 1991;69:1698-1704.
111. Kleiner SM, Calabrese LH, Fiedler KM, et al. Dietary influences on cardiovascular disease risk in anabolic steroid-using and nonusing bodybuilders. Am Coll Nutr. 1989;8:109-119.
112. Kluft C, Preston FE, Malia RG, et al. Stanozolol-induced changes in fibrinolysis and coagulation in healthy adults. Thromb Haemost. 1984;51:157-164.
113. Koenig H, Goldstone A, Lu CY (1982) Testosterone-mediated sexual dimorphism of the rodent heart. Ventricular lysosomes, mitochondria, and cell growth are modulated by androgens. Circ Res 50(6):782-787
114. Kondos GT, Hoff JA, Sevrukov A, et al. Electron-beam tomography coronary artery calcium and cardiac events: a 37-month follow-up of 5635 initially asymptomatic low- to intermediate-risk adults. Circulation. 2003;107:2571-2576.
115. Koschinsky ML. Lipoprotein(a) and atherosclerosis: new perspectives on the mechanism of action of an enigmatic lipoprotein. Curr Atheroscler Rep. 2005;7:389-395.
116. Kostner GM, Avogaro P, Cazzolato G, et al. Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis. 1981;38:51-61.
117. Kouri EM, Pope HG Jr, Oliva PS. Changes in lipoprotein-lipid levels in normal men following administration of increasing doses of testosterone cypionate. Clin J Sport Med. 1996;6:152-157.
118. Krieg A, Scharhag J, Albers T, et al. Cardiac tissue doppler in steroid users. Int J Sports Med. 2007;28:638-643.
119. Kronenberg F, Kronenberg MF, Kiechl S, et al. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. Circulation. 1999;100:1154-1160.
120. Kuipers H, Wijnen JA, Hartgens F, et al. Influence of anabolic steroids on body composition, blood pressure, lipid profile and liver functions in body builders. Int J Sports Med. 1991;12:413-418.
121. Lane HA, Grace F, Smith JC, et al. Impaired vasoreactivity in bodybuilders using androgenic anabolic steroids. Eur J Clin Invest. 2006;36:483-488.
122. Laroche GP. Steroid anabolic drugs and arterial complications in an athlete-a case history. Angiology. 1990;41:964-969.
123. Lau DH, Stiles MK, John B, et al. Atrial fibrillation and anabolic steroid abuse. Int J Cardiol. 2007;117:e86-e87.
124. Lenders JW, Demacker PN, Vos JA, et al. Deleterious effects of anabolic steroids on serum lipoproteins, blood pressure, and liver function in amateur body builders. Int J Sports Med. 1988;9:19-23.
125. Lewington S, Clarke R, Qizibash N et al (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360:1903-1913. Erratum in: Lancet. 2003 Mar 22;361(9362):1060
126. Lewis HD Jr, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1983;309:396-403.
127. Liang MTC, Paulson DJ, Kopp SJ, et al. Effects of anabolic steroids and endurance exercise on cardiac performance. Int J Sports Med. 1993;14:324-329.
128. Liljeqvist S, Helldén A, Bergman U, et al. Pulmonary embolism associated with the use of anabolic steroids. Eur J Int Med. 2008;19:214-215.
129. Lowe GD. Hormone replacement therapy: prothrombotic vs. protective effects. Pathophysiol Haemost Thromb. 2002;32:329-332.
130. Luke JL, Farb A, Virmani R, et al. Sudden cardiac death during exercise in a weight lifter using anabolic androgenic steroids: pathological and toxicological findings. J Forensic Sci. 1990;35:1441-1447.
131. Lyngberg KK (1991) Myocardial infarction and death of a body builder after using anabolic steroids. Ugeskr Laeger 153:587-588. Danish
132. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-1187.
133. Mänttäri M, Oikarinen L, Manninen V, et al. QT dispersion as a risk factor for sudden cardiac death and fatal myocardial infarction in a coronary risk population. Heart. 1997;78:268-272.
134. Mark PB, Watkins S, Dargie HJ. Cardiomyopathy induced by performance enhancing drugs in a competitive bodybuilder. Heart. 2005;91:888.
135. Marsh JD, Lehmann MH, Ritchie RH, et al. Androgen receptors mediate hypertrophy in cardiac myocytes. Circulation. 1998;98:256-261.
136. Mayet J, Shahi M, McGrath K, et al. Left ventricular hypertrophy and QT dispersion in hypertension. Hypertension. 1996;28:791-796.
137. McCarthy K, Tang ATM, Dalrymple-Hay MJR, et al. Ventricular thrombosis and systemic embolism in bodybuilders: etiology and management. Ann Thorac Surg. 2000;70:658-660.
138. McCredie RJ, McCrohon JA, Turner L, et al. Vascular reactivity is impaired in genetic females taking high-dose androgens. J Am Coll Cardiol. 1998;32:1331-1335.
139. McCrohon JA, Jessup W, Handelsman DJ, et al. Androgen exposure increases human monocyte adhesion to vascular endothelium and endothelial cell expression of vascular cell adhesion molecule-1. Circulation. 1999;99:2317-2322.
140. McCrohon JA, Death AK, Nakhla S, et al. Androgen receptor expression is greater in macrophages from male than from female donors. A sex difference with implications for atherogenesis. Circulation. 2000;101:224-226.
141. McKillop G, Todd IC, Ballantyne D. Increased left ventricular mass in a bodybuilder using anabolic steroids. Brit J Sports Med. 1986;20:151-152.
142. McNutt RA, Ferenchick GS, Kirlin PC, et al. Acute myocardial infarction in a 22-year old world class weight lifter using anabolic steroids. Am J Cardiol. 1988;62:164.
143. McQueen MJ, Hawken S, Wang X, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008;372:224-233.
144. Medras M, Tworowska U, Jozkow P, et al. Postoperative course and anabolic-androgenic steroid abuse-a case report. Anaesthesia. 2005;60:81-84.
145. Melchert RB, Welder AA. Cardiovascular effects of androgenic-anabolic steroids. Med Sci Sports Exerc. 1995;27:1252-1262.
146. Melchert RB, Harron TJ, Welder AA. The effect of anabolic-androgenic steroids on primary myocardial cell cultures. Med Sci Sports Exerc. 1992;24:206-212.
147. Menkis AH, Daniel JK, McKenzie FN, et al. Cardiac transplantation after myocardial infarction in a 24-year-old bodybuilder using anabolic steroids. Clin J Sport Med. 1991;1(2):138-140.
148. Ment J, Ludman PF. Coronary thrombus in a 23 year old anabolic steroid user. Heart. 2002;88 (4):342.
149. Mewis C, Spyridopoulos I, Kühlkamp V, et al. Manifestation of severe coronary heart disease after anabolic drug abuse. Clin Cardiol. 1996;19:153-155.
150. Mitchell TL, Pippin JJ, Devers SM, et al. Age- and sex-based nomograms from coronary artery calcium scores as determined by electron beam computed tomography. Am J Cardiol. 2001;87(453-6):A6.
151. Mochizuki RM, Richter KJ. Cardiomyopathy and cerebrovascular accident associated with anabolic-androgenic steroid use. Physician Sports Med. 1988;16:109-114.
152. Moore LG, McMurtry IF, Reeves JT. Effects of sex hormones on cardiovascular and hematologic responses to chronic hypoxia in rats (40268). Proc Soc Exp Biol Med. 1978;158:658-662.
153. Morano I, Gerstner J, Rüegg JC, et al. Regulation of myosin heavy chain expression in the hearts of hypertensive rats by testosterone. Circ Res. 1990;66:1585-1590.
154. Nakao J, Change WC, Murota SI, et al. Testosterone inhibits prostacyclin production by rat aortic smooth muscle cells in culture. Atherosclerosis. 1981;39:203-209.
155. Nicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA. 2007;297:499-508.
156. Nieminen MS, Rämö MP, Viitasalo M, et al. Serious cardiovascular side effects of large doses of anabolic steroids in weight lifters. Eur Heart J. 1996;17:1576-1583.
157. Nottin S, Nguyen L-D, Terbah M, et al. Cardiovascular effects of androgenic anabolic steroids in male bodybuilders determined by tissue doppler imaging. Am J Cardiol. 2006;97:912-915.
158. Nygård O, Nordrehaug JE, Refsum H, et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997;337:230-236.
159. O'Brien E, Sheridan J, O'Malley K. Dippers and non-dippers. Lancet. 1988;2(8607):397.
160. Palatini P, Penzo M, Racioppa A, et al. Clinical relevance of nighttime blood pressure and of daytime blood pressure variability. Arch Int Med. 1992;152:1855-1860.
161. Palatini P, Giada F, Garavelli G, et al. Cardiovascular effects of anabolic steroids in weight-trained subjects. J Clin Pharmacol. 1996;36:1132-1140.
162. Pawlowitzki IH, Diekstall P, Miny P, et al. Abnormal platelet function in Kallmann syndrome. Lancet. 1986;2(8499):166.
163. Pearson AC, Schiff M, Mrosek D, et al. Left ventricular diastolic function in weight lifters. Am J Cardiol. 1986;58:1254-1259.
164. Pedersen et al (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389
165. Pelliccia A, Maron BJ, Spataro A, et al. The upper limit of physiologic cardiac hypertrophy in highly trained elite athletes. N Engl J Med. 1991;324:295-301.
166. Pelliccia A, Spataro A, Caselli G, et al. Absence of left ventricular wall thickening in athletes engaged in intense power training. Am J Cardiol. 1993;72:1048-1054.
167. Pereira-Junior PP, Chaves EA, Costa-E-Sousa RH, et al. Cardiac autonomic dysfunction in rats chronically treated with anabolic steroid. Eur J Appl Physiol. 2006;96:487-494.
168. Perkiömäki JS, Ikäheimo MJ, Pikkujämsä SM, et al. Dispersion of the QT interval and autonomic modulation of heart rate in hypertensive men with and without left ventricular hypertrophy. Hypertension. 1996;28:16-21.
169. Pesola MK. Reversibility of the haemodynamic effects of anabolic steroids in rats. Eur J Appl Physiol. 1988;58:125-131.
170. Phillis BD, Abeywardena MY, Adams MJ, et al. Nandrolone potentiates arrhythmogenic effects of cardiac ischemia in the rat. Toxicol Sci. 2007;99:605-611.
171. Pilo R, Aharony D, Raz A. Testosterone potentiation of ionophore and ADP induced platelet aggregation: relationship to arachidonic acid metabolism. Thromb Haemost. 1981;46:538-542.
172. Pye M, Quinn AC, Cobbe SM. QT interval dispersion: a non-invasive marker of susceptibility to arrhythmia in patients with sustained ventricular arrhythmias? Br Heart J. 1994;71:511-514.
173. Rämö P, Kettunen R, Timisjärvi J, et al. Anabolic steroids alter the haemodynamic effects of endurance training on the canine left ventricle. Pflügers Arch. 1987;410:272-278.
174. Riebe D, Fernhall B, Thompson PD. The blood pressure response to exercise in anabolic steroid users. Med Sci Sports Exerc. 1992;24:633-637.
175. Rocha FL, Carmo EC, Roque FR, et al. Anabolic steroids induce cardiac renin-angiotensin system and impair the beneficial effects of aerobic training in rats. Am J Physiol Heart Circ Physiol. 2007;293:H3575-H3583.
176. Rosenblum WI, el-Sabban F, Nelson GH et al (1987) Effects in mice of testosterone and dihydrotestosterone on platelet aggregation in injured arterioles and ex vivo. Thromb Res 45:719-728
177. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993; 362:801-809.
178. Rumberger JA, Simons DB, Fitzpatrick LA, et al. Coronary artery calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area. A histopathologic correlative study. Circulation. 1995;92:2157-2162.
179. Sachtleben TR, Berg KE, Elias BA. The effects of anabolic steroids on myocardial structure and cardiovascular fitness. Med Sci Sports Excers. 1993;25:1240-1245.
180. Sachtleben TR, Berg KE, Cheatham JP. Serum lipoprotein patterns in long-term anabolic steroid users. Res Q Exerc Sport. 1997;68:110-115.
181. Sader MA, Griffiths KA, McCredie RJ, et al. Androgenic anabolic steroids and arterial structure and function in male bodybuilders. J Am Coll Cardiol. 2001;37:224-230.
182. Sader MA, Griffiths KA, Skilton MR, et al. Physiological testosterone replacement and arterial endothelial function in men. Clin Endocrinol (Oxf). 2003;59:62-67.
183. Sahraian MA, Mottamedi M, Azimi AR, et al. Androgen-induced cerebral venous sinus thrombosis in a young body builder: case report. BMC Neurol. 2004;4:22.
184. Salke RC, Rowland TW, Burke EJ. Left ventricular size and function in body builders using anabolic steroids. Med Sci Sports Exerc. 1985;17:701-704.
185. Santamarina RD, Besocke AG, Romano LM, et al. Ischemic stroke related to anabolic abuse. Clin Neuropharmacol. 2008;31:80-85.
186. Santora LJ, Marin J, Vangrow J, et al. Coronary calcification in body builders using anabolic steroids. Prev Cardiol. 2006;9:198-201.
187. Shahidi NT. Androgens and erythropoiesis. N Engl J Med. 1973;289:72-80.
188. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-1307.
189. Shiozawa Z, Yamada H, Mabuchi C, et al. Superior sagittal sinus thrombosis associated with androgen therapy for hypoplastic anemia. Ann Neurol. 1982;12:578-580.
190. Singh AB, Hsia S, Alaupovic P, et al. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J Clin Endocrinol Metab. 2002;87:136-143.
191. Small M, McArdle BM, Lowe GD, et al. The effect of intramuscular stanozolol on fibrinolysis and blood lipids. Thromb Res. 1982;28:27-36.
192. Small M, MacLean JA, McArdle BM, et al. Haemostatic effects of stanozolol in elderly medical patients. Thromb Res. 1984;35:353-358.
193. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356, 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;256:2823-2828.
194. Stevens QEJ, Dickerman RD, McConathy WJ, et al. Aortic and mitral valve thickening with concentric left ventricular hypertrophy in an elite bodybuilder: a biochemical and/or physiological adaptation? Cardiology. 2002;98:159-161.
195. Stolt A, Karila T, Viitasalo M. QT interval and QT dispersion in endurance athletes and in power athletes using large doses of anabolic steroids. Am J Cardiol. 1999;84:364-366.
196. Sullivan ML, Martinez CM, Gallagher EJ. Atrial fibrillation and anabolic steroids. J Emerg Med. 1999;17:851-857.
197. Tagarakis CV, Bloch W, Hartmann G, et al. Anabolic steroids impair the exercise-induced growth of the cardiac capillary bed. Int J Sports Med. 2000;21:412-418.
198. Taggart HM, Applebaum-Bowden D, Haffner S, et al. Reduction in high density lipoproteins by anabolic steroid (stanozolol) therapy for postmenopausal osteoporosis. Metabolism. 1982;31:1147-1152.
199. Takala TES, Kiviluoma K, Kihlström M, et al. Effects of physical training, methandione and their combination on the lysosomal hydrolytic activities in dog heart. Int J Sports Med. 1992;13:52-55.
200. Teruel JL, Marcén R, Navarro JF, et al. Evolution of serum erythropoietin after androgen administration to hemodialysis patients: a prospective study. Nephron. 1995;70:282-286.
201. Thiblin I, Lindquist O, Rajs J. Cause and manner of death among users of anabolic androgenic steroids. J Forensic Sci. 2000;45:16-23.
202. Thompson PD, Cullinane EM, Sady SP, et al. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA. 1989;261:1165-1168.
203. Thompson PD, Sadaniantz A, Cullinane EM, et al. Left ventricular function is not impaired in weight-lifters who use anabolic steroids. J Am Coll Cardiol. 1992;19:278-282.
204. Tischer KH, Heyny-von Haussen R, Mall G, et al. Koronarthrombosen und -ektasien nach langjäriger Einname von anabolen Steroiden. Z Kardiol. 2003;92:326-331.
205. Tonstad S, Joakimsen O, Stensland-Bugge E, et al. Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and control subjects. Arterioscler Thromb Vasc Biol. 1996;16:984-991.
206. Trifunovic B, Norton GR, Duffield MJ, et al. An androgenic steroid decreases left ventricular compliance in rats. Am J Physiol. 1995;268:H1096-H1105.
207. Urhausen A, Kindermann W. Sports-specific adaptations and differentiation of the athlete's heart. Sports Med. 1999;28:237-244.
208. Urhausen A, Hölpes R, Kindermann W. One- and two-dimensional echocardiography in bodybuilders using anabolic steroids. Eur J Appl Physiol. 1989;58:633-640.
209. Urhausen A, Torsten A, Kindermann W. Reversibility of the effects on blood cells, lipids, liver function and hormones in former anabolic-androgenic steroid abusers. J Steroid Biochem Mol Biol. 2003;84(2-3):369-375.
210. Urhausen A, Albers T, Kindermann W. Are the cardiac effects of anabolic steroid abuse in strength athletes reversible? Heart. 2004;90:496-501.
211. Uzunova A, Ramey E, Ramwell PW. Effect of testosterone, sex and age on experimentally induced arterial thrombosis. Nature. 1976;261:712-713.
212. Uzunova AD, Ramey ER, Ramwell PW. Arachidonate-induced thrombosis in mice: effects of gender or testosterone and estradiol administration. Prostaglandins. 1977;13:995-1002.
213. van Guldener C, Stehouwer CD. Hyperhomocysteinemia, vascular pathology, and endothelial dysfunction. Semin Thromb Hemost. 2000;26:281-289.
214. Verdecchia P. Prognostic value of ambulatory blood pressure: current evidence and clinical implications. Hypertension. 2000;35(3):844-851.
215. Verheijen JH, Rijken DC, Chang GT. Modulation of rapid plasminogen activator inhibitor in plasma by stanozolol. Thromb Haemost. 1984;51:396-397.
216. Wagner D, Metzger R, Paul M, et al. Androgen dependence and tissue specificity of renin messenger RNA expression in mice. J Hypertens. 1990;8:45-52.
217. Webb OL, Laskarzewski PM, Glueck CJ. Severe depression of high-density lipoprotein cholesterol levels in weight lifters and body builders by self-administered exogenous testosterone and anabolic-androgenic steroids. Metabolism. 1984;33:971-975.
218. White AD, Folsom AR, Chambless LE, et al. Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: methods and initial two years0 experience. J Clin Epidemiol. 1996;49:223-233.
219. Wilson JD. Androgen abuse by athletes. Endocr Rev. 1988;9:181-199.
220. Winter JH, Fenech A, Bennett B, et al. Prophylactic antithrombotic therapy with stanozolol in patients with familial antithrombin III deficiency. Br J Haematol. 1984;57:527-537.
221. Woodiwiss AJ, Trifunovic B, Philippides M, et al. Effects of an androgenic steroid on exercise-induced cardiac remodeling in rats. J Appl Physiol. 2000;2000(88):409-415.
222. Wysoczanski M, Rachko M, Bergmann SR. Acute myocardial infarction in a young man using anabolic steroids. Angiology. 2008;59(3):376-378.
223. Yeater R, Reed C, Ullrich I, et al. Resistance trained athletes using or not using anabolic steroids compared to runners: effects on cardiorespiratory variables, body composition, and plasma lipids. Br J Sports Med. 1996;30:11-14.
224. Yesalis CE, Kennedy NJ, Kopstein AN, et al. Anabolic-androgenic steroid use in the United States. JAMA. 1993;270(10):1217-1221.
225. Zaugg M, Jamali NZ, Lucchinetti E. Anabolic-androgenic steroids induce apoptotic cell death in adult rat ventricular myocytes. J Cell Physiol. 2001;187:90-95.
226. Zitzmann M, Brune M, Nieschlag E. Vascular reactivity in hypogonadal men is reduced by androgen substitution. J Clin Endocrinol Metab. 2002;87:5030-5037.
227. Zmuda JM, Fahrenbach MC, Younkin BT, et al. The effect of testosterone aromatization on high-density lipoprotein cholesterol level and postheparin lipolytic activity. Metabolism. 1993;42:446-450.
228. Zmuda JM, Bausserman LL, Maceroni D, et al. The effect of supraphysiologic doses of testosterone on fasting total homocysteine levels in normal men. Atherosclerosis. 1997;130:199-202.
229. Zmunda JM, Thompson PD, Dickenson R, et al. Testosterone decreases lipoprotein(a) in men. Am J Cardiol. 1996;77:1244-1247.
230. Zuliani U, Bernardini B, Catapano A. Effects of anabolic steroids, testosterone, and hgh on blood lipids and echocardiographic parameters in body builders. Int J Sports Med. 1989;10:62-66.